Why Test VWF on Day 3 of Menses?
Testing VWF on day 3 of the menstrual cycle is not specifically recommended by current guidelines; instead, testing should be delayed until after active menstrual bleeding and anemia have resolved to avoid falsely elevated VWF levels that can mask the diagnosis.
Current Guideline Recommendations on Timing
The 2025 VWD diagnosis guidelines explicitly recommend avoiding testing during active menstrual bleeding because acute bleeding and associated stress can artificially elevate VWF levels, which is an acute-phase reactant 1. The guidelines state that testing should be delayed until resolution of anemia and active heavy menstrual bleeding to provide a more accurate evaluation 1.
- VWF levels are affected by stress, exercise, estrogens, and pregnancy, so testing should be performed at physiologic baseline whenever possible 1.
- Ideally, samples should be drawn when the patient is in a physiologically stable state, avoiding conditions that transiently raise VWF 2, 3.
- Repeat testing is often necessary for a definitive diagnosis, especially when initial results are obtained under suboptimal conditions 1, 3.
Historical Context and Conflicting Evidence
The concept of testing on specific menstrual cycle days stems from older research showing variable VWF levels throughout the cycle, but recent evidence has produced conflicting results 4, 5:
- A 1992 study suggested that representative VWF levels might be obtained in the follicular phase (which includes day 3), proposing this as the optimal timing for diagnosis 4.
- However, a 2006 review found conflicting data: one study of 95 women showed no variation across cycle days, while another found the lowest VWF levels on days 1-4 and highest on days 9-10 5.
- A 2008 study of 246 young women found that VWF levels did not correlate with timing during the menstrual cycle 6.
Given these contradictory findings, current guidelines do not endorse testing exclusively during any specific menstrual cycle phase 5.
Why Active Bleeding Should Be Avoided
The critical issue is that active menstrual bleeding creates physiologic stress that elevates VWF levels, potentially masking VWD 1, 2:
- VWF is an acute-phase reactant that increases during inflammation and stress 3, 7.
- Testing during active bleeding or in the presence of anemia can yield false-negative results 2, 3.
- Among adolescents with heavy menstrual bleeding, approximately 39% have an underlying bleeding disorder, making accurate testing crucial 3.
Practical Clinical Approach
For women with suspected VWD presenting with heavy menstrual bleeding:
- Defer initial testing until at least several days after menstruation has completely stopped and any anemia has been addressed 1, 2.
- If testing must be performed during the cycle, avoid the active bleeding phase (days 1-2) 5.
- Consider testing in the mid-to-late follicular phase (days 4-7) or later in the cycle when bleeding has fully resolved 4, 5.
- Always plan for repeat testing if initial results are borderline or obtained under suboptimal conditions 1, 3.
- Avoid testing during pregnancy, acute illness, or while on high-dose estrogen therapy 1, 2.
Additional Pre-analytical Considerations
- Document ABO blood type, as type O individuals have VWF levels approximately 25-30% lower than non-O groups 2, 7.
- VWF levels increase approximately 1-2% per year with aging 1.
- Modern oral contraceptives contain lower estrogen doses and are less likely to significantly affect VWF levels than historical preparations, though testing off hormonal therapy may still be preferable when feasible 5, 8.
Common Pitfalls
- Testing during active menstruation or acute bleeding can falsely normalize VWF levels and lead to missed diagnoses 2, 3, 7.
- A single normal result does not exclude VWD in symptomatic patients; repeat testing is essential 1, 2.
- Failing to account for blood type O status can lead to misclassification 2, 7.